Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 97, Issue 3, 2002, Pages 714-720

  Rosen, Hugo R ^a   McHutchison, John G ^b   Conrad, Andrew J ^b   Lentz, Jennifer J ^b   Marousek, Gail ^b   Rose, Steven L ^b   Zaman, Atif ^b   Taylor, Kent ^b   Chou, Sunwen ^b  

^a Division of Gastroenterology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK BENEFIT ANALYSIS; VIRUS GENOME; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036126282     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)04114-4     Document Type: Article

References (41)

1. Combination therapy for hepatitis C infection
2. Cytokines in viral hepatitis
3. Genetic variability at the human tumor necrosis factor loci
4. Genetics of tumor necrosis factor (TNF) in autoimmune liver diseases: Red hot or red herring?
5. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion in the rat
6. Tumor necrosis factor a gene expression and the response to interferon in chronic hepatitis C
7. Cytokines and fibrogenesis
8. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C
9. Serum levels of cytokines in chronic liver diseases
10. Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease
11. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
12. Hepatitis C virus core protein enhances NF-B signal pathway triggering by lymphotoxin-'62 receptor ligand and tumor necrosis factor alpha
13. The -308 tumour necrosis factor alpha promoter polymorphism affects transcription
14. Effects of a polymorphism in the human tumor necrosis factor '61 on transcriptional activation
15. Tumour necrosis factor (TNF) gene polymorphism influences TNF-a production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans
16. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome
17. Genetic influence on cytokine production in meningococcal disease
18. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria
19. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles
20. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
21. Polymorphic structure of the tumor necrosis factor (TNF) locus: An Nco1 polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production
22. Histopathology of hepatitis C virus infection
23. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
24. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
25. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis
26. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus
27. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C
28. Soluble tumor necrosis factor receptors in chronic hepatitis C: A correlation with histological fibrosis and activity
29. Determination of hepatitis C virus-specific effector/memory CD4+ T cell frequencies at different clinical stages of disease
30. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
31. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease
32. Polymorphisms of the TNF-a gene promoter region in hepatitis C infection
33. Chronic viral hepatitis and the human genome
34. Interferon alfa 2-b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
35. Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized controlled trials
36. Overview of interferon therapy for chronic hepatitis C
37. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, and the procoagulant fgl 2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response
38. A new TNFA promoter allele identified in South American blacks
39. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection
40. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection